EHS
EHS

IBD uncommon in PsA, psoriasis, AS following secukinumab treatment



Inflammatory bowel disease events, including Crohn’s disease and ulcerative colitis, are uncommon in patients with psoriatic arthritis, psoriasis and ankylosing spondylitis who were treated with secukinumab, according to data published in the Annals of the Rheumatic Diseases.
“Patients with [psoriasis], PsA and AS have a 1–4-fold increased risk, relative to the background population, of developing IBD,” Stefan Schreiber, MD, PhD, of University Hospital Schleswig Holstein, Christian-Alrechts-University in Germany, and colleagues wrote. “Secukinumab, a fully human

Source link

EHS
Back to top button